Prof Martin Reck speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.
He discusses the CheckMate 9LA trial which looks at nivolumab ipilimumab 2 cycles of platinum-doublet chemotherapy versus 4 cycles chemo as first-line treatment for stage IV/recurrent non-small cell lung cancer (NSCLC).
Prof Reck outlines the background and reasoning for trialling the combination of checkpoint inhibitors, with the addition of 2 cycles of chemo.
He gives a detailed description of the positive response for the combination arm, and outlines the toxicities which were expected, and manageable, with these particular drugs.
This programme has been supported by an unrestricted educational grant from Bristol Myers Squibb.